All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
CA057-003: Mezigdomide + dexamethasone in novel-novel combination for RRMM
Bookmark this article
|
MEZI is a novel potent oral immunomodulatory drug, showing promising clinical activity with DEX. Preliminary results from the CA057-003 trial (NCT05372354) evaluating the safety and efficacy of MEZI + DEX (MEZId) plus novel-novel targeted triplet combination of TAX, BMS-986158, or TRAM in patients with RRMM who are intolerant or unsuitable for existing therapies (n = 56) were presented by Luciano Costa at the 66th ASH Annual Meeting and Exposition.1 |
| Key learnings |
| ≥1 DLTs were observed in 6.7%, 27.8%, and 10.5% of patients in the MEZId + TAZ, MEZId + BMS-986158, and MEZId + TRAM cohorts, respectively. All doses were well tolerated except DL3 in the MEZId + BMS-986158 cohorts. |
| Grade ≥3 neutropenia was experienced by 50.0%, 65.0%, and 80.0% of patients in the MEZId + TAZ, MEZId + BMS-986158, and MEZId + TRAM cohorts, respectively. No new safety signals were identified, and non-hematologic TEAEs were infrequent across all cohorts. |
| The ORR at all doses was 50.0%, 35.0%, and 75.0% in the MEZId + TAZ, MEZId + BMS-986158, and MEZId + TRAM cohorts, respectively. The pharmacodynamic activity of MEZI 1.0 mg was preserved in all combinations. |
| These preliminary findings suggest that MEZId in combination with TAZ, BMS-986158, or TRAM showed promising efficacy and a manageable safety profile, warranting further investigation. |
Abbreviations: DEX, dexamethasone; DL, dose level; DLT, dose-limiting toxicity; MEZI, mezigdomide; MEZId, mezigdomide plus dexamethasone; ORR, overall response rate; RRMM, relapsed/refractory multiple myeloma; TAZ, tazemetostat; TEAE, treatment-emergent adverse event; TRAM, trametinib.
- Costa L. Mezigdomide (MEZI) in novel-novel combinations for relapsed or refractory multiple myeloma (RRMM): Preliminary results from the CA057-003 trial. Oral abstract #677. Presented at: 66th ASH Annual Meeting and Exposition; Dec 7–10, 2024; San Diego, US.
Your opinion matters
1 vote - 54 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox